Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Non-cash Items (2016 - 2018)

Historic Non-cash Items for Vanda Pharmaceuticals (VNDA) over the last 9 years, with Q1 2018 value amounting to $28.6 million.

  • Vanda Pharmaceuticals' Non-cash Items rose 3233.5% to $28.6 million in Q1 2018 from the same period last year, while for Mar 2018 it was $28.6 million, marking a year-over-year increase of 3233.5%. This contributed to the annual value of $3.5 million for FY2017, which is 8908.94% down from last year.
  • According to the latest figures from Q1 2018, Vanda Pharmaceuticals' Non-cash Items is $28.6 million, which was up 3233.5% from $3.5 million recorded in Q4 2017.
  • Vanda Pharmaceuticals' 5-year Non-cash Items high stood at $3.3 billion for Q2 2017, and its period low was $3.5 million during Q4 2017.
  • Moreover, its 5-year median value for Non-cash Items was $21.6 million (2017), whereas its average is $211.6 million.
  • Examining YoY changes over the last 5 years, Vanda Pharmaceuticals' Non-cash Items showed a top increase of 2469774.57% in 2017 and a maximum decrease of 8908.94% in 2017.
  • Over the past 5 years, Vanda Pharmaceuticals' Non-cash Items (Quarter) stood at $28.5 million in 2014, then crashed by 73.71% to $7.5 million in 2015, then soared by 332.82% to $32.5 million in 2016, then crashed by 89.09% to $3.5 million in 2017, then surged by 707.36% to $28.6 million in 2018.
  • Its Non-cash Items stands at $28.6 million for Q1 2018, versus $3.5 million for Q4 2017 and $37.4 million for Q3 2017.